Markus Moehler
Mainz, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
EORTC-1607-GITCG/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer.
Journal: Translational oncology
Published: March 28, 2026
Immune Checkpoint Inhibitor Therapy for Advanced, Unresectable Esophageal Squamous Cell Carcinoma: A Series of Patient-level Meta-analyses From Phase III Trials.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: October 07, 2025
What Is New in the German S3 Guideline on Gastric Cancer: Diagnosis, Staging, and Treatment.
Journal: Oncology research and treatment
Published: October 06, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.
Journal: Advances in therapy
Published: August 13, 2025
Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic cancer patients: study protocol of the European multicenter randomized controlled trial of the RELEVIUM project.
Journal: BMC cancer
Published: July 28, 2025
PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups.
Journal: Critical reviews in oncology/hematology
Published: May 29, 2025
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2022
Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support?
Journal: Journal of gastrointestinal and liver diseases : JGLD
Published: October 29, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 17, 2019
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).
Journal: Cancer chemotherapy and pharmacology
Published: April 07, 2018
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Journal: Cancer treatment reviews
Published: January 29, 2018
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.
Journal: Critical reviews in oncology/hematology
Published: January 08, 2018
Last Updated: 09/26/2026